numares at a glance company overview 2014 Discover, understand and use biological systems high level NMR analytics

Similar documents
LIPOPROTEIN PROFILING

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

Bringing metabolic profiling into clinical practice. Linda Mustelin, MD, PhD, MPH Senior Medical Scientist Nightingale Health

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI

CyBio Felix Your Automated Application Starts Here

Mass Spectrometry Made Simple for Clinical Diagnostic Labs

Patient Stratification and Precision Medicine in Pancreatic Cancer

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery

NAVIFY Tumor Board NAVIFY

Engaging patients and providers with the right information, at the right time, to do the right thing

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

AN INTRODUCTION TO YPSODOSE FOR THE LARGE-VOLUME INJECTION OF BIOLOGICS

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

LC/MS/MS SOLUTIONS FOR LIPIDOMICS. Biomarker and Omics Solutions FOR DISCOVERY AND TARGETED LIPIDOMICS

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

The IVDr Platform Concept and Enabling Tools. M.Spraul, H.Schäfer, C.Cannet, F.Fang Bruker BioSpin Biobank Webinar 2018

Quality Management System Certification. Understanding Quality Management System (QMS) certification

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

From HDL Structure to Function - How Structural Information Can Help Address Clinical Need March 17, 2012

Comprehensive Tumor Profiling of Immune Response and Systems Biology. HTG EdgeSeq Immuno-Oncology Assay. HTG EdgeSeq Oncology Biomarker Panel

Coverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests

NMR for Industrial and Clinical Applications

The Journey towards Total Wellbeing A Health System s Innovative Approach

Clinical Metabolomics by 1. H-NMR Spectroscopy

Accelerate Your Research with Conversant Bio

Abaxis Piccolo xpress TM

BIOCRATES Life Sciences AG

TESTIA For INNOVATIVE Solutions

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

Background Information

V8 NEXUS. Glyco Liver Profile NA2 NA3 NA2FB NGA2F. The next generation in non-invasive liver diagnostics INFLAMMATION FIBROSIS CIRRHOSIS HCC

概美科技. GuideMia Technologies, LLC Sept

Wilmad Your One Stop NMR Shop

Innovator Case Studies: Oncology Networks

Why do we need SD LipidoCare?

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

PREDIABETES TESTING SERVICES

Test Definition: FNMR2 NMR LipoProfile w/ir Markers

the minispec mq one TD-NMR Analyzers

Plans for the Precision Cancer Medicine Institute University of Oxford

Metabonomics and MRS BCMB/CHEM 8190

Vicore Pharma AB. Audiocast, October 2, Presentation by Per Jansson, CEO and Ulrike Muscha Steckelings, CSO

Consumer Health Care V5.0_2013

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Alere Technologies GmbH

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

A. CANDIDATE S BACKGROUND I am committed to an academic research career as an independent investigator and leader in identifying and understanding

Partner with the Global Leader in Drug Delivery Systems.

Novel Diagnostics and Biomarker Opportunities

Partner with the Global Leader in Drug Delivery Systems.

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

ISO 13485:2016 MEDICAL DEVICES QMS TRANSITION GUIDE

Kidney Cancer Diagnostic Kit

TIME IS THE KEY IN CANCER DIAGNOSTICS. THIS IS WHY WE HAVE CREATED INPROBE MINIMALLY INVASIVE MEDICAL DEVICE CAPABLE OF REAL-TIME DIAGNOSTICS OF HER2

THE PHASE I/II CLINICAL TRIAL IN PATIENTS WITH BLADDER CANCER

Lipid Management 2013 Statin Benefit Groups

Personalized medecine Biomarker

Dicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies

Biomarker strategy for Personalized Healthcare at Roche

PRA International Early Development Services Bioanalytical Laboratory

Radiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions

= AUDIO. Managing Diabetes for Improved Cardiovascular Health. An Important Reminder. Mission of OFMQ 8/18/2015. Jimmi Norris MS, RN, CDE

Lipoprotein Particle Profile

NEW! KIBION DYNAMIC 13 C BREATH TEST ANALYSER. Rapid and reliable diagnosis of Helicobacter pylori infections

A GUIDE TO UPGRADING YOUR SAP HYBRIS COMMERCE PLATFORM

For personal use only. Investor Briefing. Bayswater, 1 st December 2016

Myriad Genetics mychoice HRD Update 06/30/2016

QIAGEN's Growing Immuno-Oncology Testing Portfolio

Photocure ASA Executing the Strategy

CARDIO Test INFAI. for Cardiac Risk Assessment

QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing

Dysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

JOSLIN INGENUITY DIGITAL IMPACT INNOVATION BIG DATA CAPACITY TRANSLATIONAL AGILITY COLLABORATION COLLABORATION JENESIS

Systems Thinking in Personalized Medicine

Genomas, Inc. COMPANY PROFILE

KiOnutrime-CsG The proven weight management tool

Join the mass movement towards mass spectrometry

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

LIGHT SERIES MULTIPLE WAVELENGTHS FOR THE HIGHEST CHALLENGES IN LASER APPLICATIONS

BIOMARKER ELISAs for CLINICAL RESEARCH

Solutions at GE Inspection Technologies

Cardiovascular Health Controlling Both HDL And LDL is Important

Certified Health IT Transparency and Disclosure Information 2014 Edition

Innovator in Chelated Mineral Nutrition

Opportunities and Challenges in the Development of Companion Diagnostics

Titan power The best just got better. Impedance, OAE, ABRIS and the revolutionary Wideband Tympanometry in one powerful device.

Joachim Eberle Head of R&D, Roche Centralized Diagnostics

Personalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D

Supporting positive clinical outcomes. Hospital and patient care product offering

Vision and strategies to Increase Access to Innovative HIV Diagnostic Technologies. Willy Urassa. AMD STAKE HOLDERS MEETING 7-8 May 2013

Introducing BSI. BSI Medical Device Regulatory Update Galway, Ireland. Dr. Michael Weissig EMEA Vice President Healthcare 26 June, 2015

Technical Bulletin. Cholesterol Reference Method Laboratory Network (CRMLN) Overview. TB Rev. 0

NMR ANNOTATION. Rémi Servien Patrick Tardivel Marie Tremblay-Franco Cécile Canlet 01/06/2017 v 1.0.0

IBA Dosimetry Company Presentation. Patient Safety & Quality Control

CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

ASX Announcement 22 June 2017

Customer Bulletin January 2017

Transcription:

numares at a glance company overview 2014 Discover, understand and use biological systems high level NMR analytics

Three benefits of numares 1 Supporting patients to receive better cure based on effective diagnosis for their disease 2 3 Providing physicians better information for treatment decisions (unmet medical need) Providing Laboratories (hospitals / commercial) a new diagnostic platform for cost efficient, fully automated testing in routine operations numares develops and sells new diagnostic tests, based on magnetic resonance spectroscopy (NMR) and specialized evaluation algorithm for metabolic profiles offering also various possibilities in pharma development (e.g. clinical studies)

numares HEALTH companyoverview numares HEALTH is an IVD system provider and IVD test manufacturer Founded 2004 as a spin off from Regensburg University, Department of Medical Physics Strategic cooperation with worldwide leading laboratory group (customer) and NMR manufacturer Bruker Corp. (supplier) Up to today 12 successful installation of numares NMR instruments at US customer sites processing in 24/7 operations 2,500 to 3,000 patient samples a day Launch of the first CE IVD dedicated NMR system and the first CE IVD test for lipoproteins in cardiovascular diseases in 2014 Several tests in oncology and nephrology are in the development pipeline

numares HEALTH infrastructure 3 laboratories with GMP status as a testing laboratory for pharmaceuticals State of the art NMR equipment for fully automated high throughput analyses Sample capacity of several hundreds of samples/day/platform 2013: certification acc. to EN ISO 13485 as an in vitro diagnostics (IVD) manufacturer Quality management systems, certified acc. to ISO 9001 and EN ISO 13485 Interdisciplinary team of scientists and experts with a strong background in medicine, physics, (bio)informatics and (bio)chemistry

The clue: Metabolism is a concert, a disease causes a disharmony The numares NMR is like an advanced stethoscope for the physician. The human metabolism is the outcome of the activities of the proteome, it is like an orchestra playing beautiful music. A disease can be seen like a disharmony of tones. A metabolic profile can diagnose a disease. It is about the ratios of metabolites instead of absolute concentrations which are used so far as diagnostics.

AXINON test system AXINON an IVD and Life Science test system Easy access to metabolic data Meaningful results for medical questions Multi testing flexibility Processing of different sample matrices Fully automated lab solution

Business model system provider for high throughput metabolic profiling IVD NMR instrument portfolio low/medium throughput 80/150 samples per day (*) medium/high throughput 300/450 samples per day Service portfolio Two sites US and Europe NMR application specialists and IT experts AXINON platform - IVD NMR instrument - Software suite for IVD tests Customer Service - training - repairs / maintenance numares is a system business provider IVD Test kits - tubes / caps - calibrator / controls Workflow integration - LIMS / IT connectivity - sample flow IVD Test portfolio Lipoproteins Prostate Cancer (*) Urothelial cancer (*) Nephropathy (*) Coronary artery disease (*) Allograph rejection (*) Interface numares system / laboratory information system (LIMS) steered by individual bar coded sample tubes to ensure data integrity * Under development, availability depends on regulatory clearance

Test system workflow Laboratory workflow Automatic Starting Recording a Using numares Preparing numares The NMR is a fully automated, easy calculation NMR predefined to use diagnostic predefined system NMR samples of metabolites measurement numares spectrum metabolic profiles with a disruptive cost position. concentrations Calculating diagnostic test/patient result numares AXINON test system, IP protected Cost position Licence fee for numares IP Consumable costs tubes reagents Fix costs NMR instrument infrastructure labour costs 40% 32% 28% 57% 23% 20% 67% 18% 15% Price per test / result (example) 9,90 29% 6,97 14% 5,98 one test two tests three tests one test two tests three tests

AXINON lipofit test system Advanced Lipoprotein subclasses profiling Particle concentration in lipoprotein (sub)fractions Mean particle sizes in VLDL, LDL and HDL fractions Cholesterol concentrations* in lipoprotein fractions and subfractions Standard lipid panel (total cholesterol, triglycerides) Metabolic parameters (Glucose, Lactate, Alanine, Valine, Leucine, Isoleucine) Easy to operate system, minimal sample preparation Processing exclusively on the AXINON IVD platform Cost effective, time saving, highly reproducible data *These parameters have been calibrated against several alternative methods.

AXINON lipofit test system applications Applications in pharma research & development Characterization of the therapeutic profile of new (lipid lowering) drugs targeting cardiovascular disease (CVD) and metabolic disorders Patient stratification in clinical studies: improve candidate selection and reduce biological variability Advanced lipoprotein parameters as potential Companion Diagnostics Post approval drug surveillance

Our approach reading metabolic profiles numares offers you tests for (pharmaco )metabolic and lipoprotein profiling. numares unique NMR expertise to read out the patient s metabolic state and use the information provided can boost discovery, development and monitoring of drug products. Prediction of drug targets Discovery of biomarkers Patient stratification Drug efficacy studies Pharmacokinetics Toxicity evaluation AXINON unique test system for several pharma development questions

AXINON test system productpipeline numares successfully applies metabolic and lipoprotein profiling combining highlevel NMR techniques with patented statistical methods for developing innovative test systems for IVD and research use. Coronary artery disease (CAD) CAD risk assessment based on lipoprotein subfraction analysis Several sample sets from different study cohorts analyzed Test system successfully established in clinical diagnostic routine use (US) Prostate cancer Test for staging/grading of prostate cancer using urinary metabolomics Pilot study completed, data analysis in progress Renal allograft rejection Test for early diagnosis after NTX using urinary metabolomics Retrospective clinical trial and prospective study completed Nephrology Test for detecting impaired renal function Interpretation of metabolic profiles from urine

Metabolic networks for detection of renal allograft rejection Patient A kidney function shows normal ratios e.g. urine of patients without kidney damage metabolic profile kidney OK Patient B kidney function shows adverse ratios, risks for potential rejection Gemessene metabolic profile NOT-OK e.g. urine of patients with kidney damage

numares your contact partners Dr. Volker Pfahlert Executive President, numares AG Email: volker.pfahlert@numares.com Dr. Eric Schiffer Head of Clinical Research Unit, numares AG Email: eric.schiffer@numares.com

Thank you Discover, understand and use biological systems high level NMR analytics